Traws Pharma, Inc. Share Price Today: Live Updates & Key Insights

Traws Pharma, Inc. share price today is $2.1, up -1.83%. The stock opened at $2.13 against the previous close of $2.18, with an intraday high of $2.18 and low of $2.09.

Traws Pharma, Inc. Share Price Chart

Traws Pharma, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Traws Pharma, Inc. Share Price Performance

$2.1 -0.0183(-1.83%) TRAW at 23 Mar 2026 03:33 PM Biotechnology
Lowest Today 2.09
Highest Today 2.18
Today’s Open 2.13
Prev. Close 2.18
52 Week High 3.27
52 Week Low 0.97
Day’s Range: Low 2.09 High 2.18
52-Week Range: Low 0.97 High 3.27
1 day return -
1 Week return -0.47
1 month return +47.18
3 month return +59.54
6 month return +10.58
1 year return -26.14
3 year return +187.68
5 year return -88.09
10 year return -

Traws Pharma, Inc. Institutional Holdings

Traws Pharma, Inc. Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Traws Pharma, Inc. Fundamentals

Market Cap 19.42 M

PB Ratio 3.7097

PE Ratio 0.0

Enterprise Value 10.44 M

Total Assets 24.96 M

Volume 58486

Traws Pharma, Inc. Company Financials

Annual Revenue FY23:226000 0.2M

Annual Profit FY23:210000 0.2M

Annual Net worth FY23:-18948000 -18.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:2733000 2.7M, Q1/2025:57000 0.1M, Q3/2024:57000 0.1M, Q2/2024:57000 0.1M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:2733000 2.7M, Q1/2025:56000 0.1M, Q3/2024:57000 0.1M, Q2/2024:53000 0.1M

Quarterly Net worth Q3/2025:-3035000 -3.0M, Q2/2025:-625000 -0.6M, Q1/2025:15083000 15.1M, Q3/2024:-8475000 -8.5M, Q2/2024:-123143000 -123.1M

About Traws Pharma, Inc. & investment objective

Company Information Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Dr. Iain D. Dukes DPHIL, M.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Traws Pharma, Inc. FAQs

What is the share price of Traws Pharma, Inc. today?

The current share price of Traws Pharma, Inc. is $2.1.

Can I buy Traws Pharma, Inc. shares in India?

Yes, Indian investors can buy Traws Pharma, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Traws Pharma, Inc. shares in India?

You can easily invest in Traws Pharma, Inc. shares from India by:

Can I buy fractional shares of Traws Pharma, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Traws Pharma, Inc.?

Traws Pharma, Inc. has a market cap of $19.42 M.

In which sector does Traws Pharma, Inc. belong?

Traws Pharma, Inc. operates in the Biotechnology sector.

What documents are required to invest in Traws Pharma, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Traws Pharma, Inc.?

The PE ratio of Traws Pharma, Inc. is N/A and the PB ratio is 3.71.